Endpoint Waiver & No-New-Testing Justification Toolkit
Help medical-device teams prepare traceable, endpoint-specific records explaining why an endpoint is not applicable, why existing evidence may support a proposal not to generate new test data, or why additional evidence or testing remains necessary.
Package at a glance
11 ZIP entries
The current customer archive passed exact-inventory, checksum, and deterministic-rebuild QA.
18 workbook sheets
A fail-closed working system with sample content kept separate.
3-page Quick Start
A concise route through the files, controls, and escalation points.
32 official sources
Source status, limitations, retrieval dates, and recheck triggers.
A traceable working record—not a shortcut to a conclusion
Endpoint applicability, evidence bridges, jurisdiction-specific rationale, limitations, stress testing, and qualified scientific approval
Controlled Endpoint Dispositions
A controlled question tied to the exact final finished device, intended use, contact route, cumulative duration, population, materials, processing, sterilization, packaging, shelf life, and jurisdiction.
Traceable Evidence Bridges
An endpoint register that separates applicability from evidence sufficiency and never turns a generic table into an automatic test plan.
Jurisdiction-Specific Rationale
A provenance-controlled evidence inventory and an explicit comparison showing what each prior report, chemistry record, TRA, publication, clinical/PMS source, or risk record can and cannot support.
Qualified Review Handoff
A clear distinction among endpoint not applicable, endpoint addressed without new testing, testing or other evidence required, and unresolved qualified-review escalation.
What the current customer edition contains
The verified v3.0 archive contains 9 buyer payload files plus MANIFEST.csv and SHA-256 checksums. Final document, workbook, visual, and archive-integrity QA are complete.
Quick Start PDF
Run the controlled workflow in the correct order and understand every stop condition.
Complete when: The device, endpoint, evidence, market, required records, and qualified-review route are clear.
Implementation Guide PDF
Apply the full endpoint-applicability, prior-evidence, chemistry/TRA, jurisdiction, rationale, stress-test, and close-out method.
Complete when: A reviewer can reconstruct why the endpoint was considered, how the evidence applies, what remains uncertain, and who owns the decision.
Editable Working Templates DOCX
Draft thirteen controlled records for a real device without importing the fictional example into live evidence.
Complete when: Every instruction field contains device-specific content and every terminal position is linked to a named qualified decision.
Operational Workbook XLSX
Control scope, endpoints, evidence, applicability, changes, chemistry/TRA, literature/PMS, jurisdictions, rationales, challenges, gaps, red flags, actions, reviews, and sources.
Complete when: Every seeded endpoint and red flag is assessed and no formula has been mistaken for scientific approval.
Source Status and Release Notes PDF
Review the official ISO, FDA, EU, CDSCO, MDCG, and eCFR source status behind the candidate.
Complete when: Edition, recognition extent, harmonisation, legal/guidance status, checked date, and recheck trigger fit the intended market.
README, responsible-use terms, source register, manifest, and checksums
Orient the buyer and preserve package identity and integrity.
Complete when: Product ID, version, inventory, hashes, professional-use boundary, and support route agree across delivery.
Inspect the actual working system
These are direct renders of the current v3.0 workbook prepared as public product views, not marketing mock-ups. Select any image to inspect it at full size.
How the resource is intended to be used
The complete Quick Start and implementation guide are included in the current v3.0 customer edition. This public walkthrough lets a buyer inspect the operating logic and stop conditions before requesting an exact offer.
Controlled scope baseline
Freeze the exact device, decision event, endpoint question, and market.
Stop if: The final finished configuration, contact, cumulative exposure, change state, population, or intended jurisdiction is unclear.
Endpoint register
Identify every endpoint that requires a documented disposition.
Stop if: A generic endpoint table is being used as an automatic checklist or an endpoint has been omitted without a device-specific basis.
Evidence inventory
Inventory the evidence and control its provenance before interpreting it.
Stop if: A relied-on report, standard, publication, dataset, translation, or source version cannot be retrieved and verified.
Applicability and change-impact record
Compare each evidence subject with the current device and exact biological question.
Stop if: Similarity rests on a material name, family label, predicate, prior acceptance, or unsupported equivalence statement.
Jurisdiction matrix
Separate the market-specific rule, guidance, recognition, or technical position.
Stop if: ISO publication, FDA recognition, EU harmonisation, law, guidance, or CDSCO FAQ language is being treated as interchangeable.
Justification record
Draft the endpoint disposition and rationale with limitations and contrary evidence visible.
Stop if: The rationale is a conclusion-first paragraph, a report list, a pass/fail recital, or an assertion that testing adds no value without a traceable evidence chain.
Reviewer challenge and remediation record
Stress-test the rationale and convert uncertainty into proportionate actions or alternatives.
Stop if: A credible contrary explanation, change, signal, source-status issue, or reviewer question remains unanswered.
Qualified review handoff
Obtain named qualified decisions and bind them to the exact candidate.
Stop if: Evidence, rationale, limitations, reviewer competence, date, decision ID, recheck trigger, or candidate identity is missing.
Current public authorities behind the working controls
Sources were checked 2026-08-02; next planned portfolio recheck is 2026-11-02. Live status must still be verified at each material decision or submission event.
ISO · ISO 10993-1:2025 catalog record
Published sixth edition dated 2025-11. Obtain and control a lawful copy; the toolkit does not reproduce protected standard text.
FDA · Recognition record 2-313 - ISO 10993-1:2025
Partial recognition entered 2026-05-25. Clause 6.9 and specified text are excluded; Notes 1-2 and the ISO 14971 conflict must be read before FDA use.
FDA · Recognition record 2-258 - ISO 10993-1:2018
Superseded recognition remains in FDA's transition for declarations of conformity through 2029-07-01, subject to the live record and submission context.
FDA · Use of International Standard ISO 10993-1 - final guidance
Final nonbinding guidance issued 2023-09-08. Use it with current recognition 2-313, device-specific guidance, and the exact submission question.
FDA · Biocompatibility Assessment Resource Center
Current FDA educational hub; it does not replace applicable policy, guidance, law, or device-specific requirements.
FDA · Basics of Biocompatibility: Information Needed for Assessment
Current FDA educational resource verified active on the checked date.
What the resource deliberately does not promise
Clear boundaries protect the buyer and make the working records more useful to qualified reviewers.
Clear boundary 1
No automated endpoint applicability, evidence sufficiency, testing recommendation, waiver approval, toxicological conclusion or biological-safety decision.
Clear boundary 2
No claim that prior testing, same material, same family, predicate, CE marking, prior clearance, complaint history or a chemistry/TRA report automatically applies to the current device.
Clear boundary 3
No claim that ISO publication equals FDA recognition, EU harmonisation, CDSCO acceptance, regulator agreement or device conformity.
Clear boundary 4
No reproduction of protected standards text or replacement for controlled standards, current law, regulator guidance, device-specific requirements and qualified review.
Questions to settle before requesting an offer
Is the current v3.0 edition available?
Yes. The current v3.0 customer edition is released and available by request. Online checkout, payment, customer download, and automatic delivery are not currently enabled. Use Request Exact Offer to receive the controlled offer before deciding whether to pay.
What is included in the current v3.0 edition?
The verified archive contains 11 ZIP entries: 9 buyer payload files plus MANIFEST.csv and SHA-256 checksums. It includes a 3-page Quick Start, 23-page implementation guide, 15-page editable templates, and 18-sheet workbook. Final document, workbook, visual, and archive-integrity QA are complete.
Does the resource provide a completed regulatory or biological conclusion?
No. It provides a traceable working system. Device-specific conclusions, testing decisions, toxicological judgments, and submission decisions require qualified review.
Can I inspect the product before requesting an offer?
Yes. This page shows the complete workflow and real v3.0 product views, while the downloadable 6-page public preview explains the scope, operating logic, included files, and important limits.
How ISO 10993 Test-Waiver Justification Works
Learn how existing evidence, chemistry, toxicology and scientific rationale can address an endpoint without treating a waiver as a shortcut.
Review the workflow now. Request the exact current offer.
No order, payment, customer download, or delivery is created through this page. The controlled offer identifies the exact version, licence, price, update option, policies, and delivery method for your review before any payment decision.